Close

More on RVU

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Friends, Peers and Foes (?): 9Y4 0RKT (more...)

Apr 10, 2024 03:00 AM Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Mar 13, 2024 04:38 AM Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
Mar 6, 2024 10:42 AM Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
Mar 6, 2024 04:41 AM Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Feb 14, 2024 01:12 PM Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
Jan 31, 2024 12:21 PM Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
Nov 2, 2023 11:03 AM Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Oct 20, 2023 02:00 AM Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
Oct 16, 2023 02:46 AM Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 14, 2023 12:08 PM Ryvu Therapeutics' Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
View All Articles

Entities mentioned with RVU

View All Entities